ACE Report Cover
No clear benefit of liposomal bupivacaine over plain bupivacaine for periarticular injection in TKA
Language
Download
Cite
+ Favorites
Language
Download
Cite
+ Favorites
AceReport Image
ARTHROPLASTY
No clear benefit of liposomal bupivacaine over plain bupivacaine for periarticular injection in TKA .

Liposomal Bupivacaine vs Plain Bupivacaine in Periarticular Injection for Control of Pain and Early Motion in Total Knee Arthroplasty: A Randomized, Prospective Study

J Arthroplasty. 2018 Aug;33(8):2460-2464 doi: 10.1016/j.arth.2018.03.014

80 patients scheduled for total knee arthroplasty were randomized to periarticular infiltration analgesia completed using either liposomal bupivacaine or plain bupivacaine. Outcomes of interest included pain scores during physical therapy, narcotic consumption, and knee range of motion. Assessment timepoints included 24 hours, 48 hours, 72 hours, and at discharge. While pain scores during physical therapy were significantly lower in the liposomal bupivacaine group at 24 hours after surgery, the differences between groups at 48 hours after surgery and all other outcome measures were not statistically significant.

Unlock the Full ACE Report

You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or upgrade today and gain access to all OrthoEvidence
content for as little as $1.99 per week.
0 of 4 monthly FREE articles unlocked
You've reached your limit of 4 free articles views this month

Access to OrthoEvidence for as little as $1.99 per week.

Stay connected with latest evidence. Cancel at any time.
  • Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
  • Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
  • Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Upgrade
Welcome Back!
Forgot Password?
Start your FREE trial today!

Account will be affiliated with


OR
Forgot Password?

OR
Please check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see an email, please check your spam or junk folder.

For further assistance, contact our support team.

Translate ACE Report

OrthoEvidence utilizes a third-party translation service to make content accessible in multiple languages. Please note that while every effort is made to ensure accuracy, translations may not always be perfect.

Cite this ACE Report

OrthoEvidence. No clear benefit of liposomal bupivacaine over plain bupivacaine for periarticular injection in TKA. ACE Report. 2018;7(10):23. Available from: https://myorthoevidence.com/AceReport/Show/no-clear-benefit-of-liposomal-bupivacaine-over-plain-bupivacaine-for-periarticular-injection-in-tka

Copy Citation
Please login to enable this feature

To access this feature, you must be logged into an active OrthoEvidence account. Please log in or create a FREE trial account.

Premium Member Feature

To access this feature, you must be logged into a premium OrthoEvidence account.

Share this ACE Report